Targeted Radiation, Unintended Evolution
Radioligand therapy exemplifies precision oncology, yet its consequences remain incompletely understood. A recent article shows that [177Lu]Lu-PSMA promotes emergence and expansion of clonal hematopoiesis enriched for DNA damage response gene mutations, reframing bone marrow effects as treatment-emergent clonal selection rather than collateral toxicity and informing biology-guided patient monitoring and theranostics.
Authors
- Gunhild von Amsberg (ORCID: https://orcid.org/0000-0002-5176-0507)
- Katharina Lueckerath (ORCID: https://orcid.org/0000-0001-6109-2066)
- Boris Hadaschik
- Ken Herrmann (ORCID: https://orcid.org/0000-0002-9662-7259)
Institutions
- Universität Hamburg (DE)
- Martini-Klinik (DE)
- Essen University Hospital (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0720
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation